The role of dexmedetomidine in decreasing acute kidney injury in children with acyanotic heart disease undergoing total correction by a new urinary biomarker kidney injury molecule-1 /
Sarah Abdelsalam Elmetwally Kasem
The role of dexmedetomidine in decreasing acute kidney injury in children with acyanotic heart disease undergoing total correction by a new urinary biomarker kidney injury molecule-1 / دور عقار الدكسميدتوميدين في تقليل الإصابة الكلوية الحادة عند الأطفال المصابين بأمراض القلب اللازرقية الذين يخضعون للتصحيح الكامل بإستخدام الدلالة البولية الحديثة "كيم -1" Sarah Abdelsalam Elmetwally Kasem ; Supervised Azza Mohamed Ezzat , Wafaa Mohamed Alsadek , Olfat Gamil Shaker - Cairo : Sarah Abdelsalam Elmetwally Kasem , 2014 - 132 Leaves : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Anaesthesia
Cardiac surgery with cardiopulmonary bypass (CPB) is the most frequent major surgical procedure worldwide. Acute kidney injury (AKI) is a common and serious complication encountered in 3040% after CPB. Once AKI is established, there is no effective treatment for human AKI, and dialysis merely provides supportive care. There in lies the Achilles heel of AKI management ; the paucity of early biomarkers has lead to an unacceptable delay in initiating therapy in humans.Serum creatinine is insensitive for the early detection of AKI. KIM-1 is one of the most highly induced proteins in the kidney after AKI in animal models, and a proteolytically processed domain of KIM-1 is easily detected in the urine soon after AKI. In a small human cross-sectional study, KIM-1 expression was markedly induced in proximal tubules in kidney biopsies from patients with established AKI (primarily ischemic), and urinary KIM-1 measured by ELISA distinguished ischemic AKI from prerenal azotemia and chronic renal disease
AKI Cardiopulmonary bypass Dexmedetomidine
The role of dexmedetomidine in decreasing acute kidney injury in children with acyanotic heart disease undergoing total correction by a new urinary biomarker kidney injury molecule-1 / دور عقار الدكسميدتوميدين في تقليل الإصابة الكلوية الحادة عند الأطفال المصابين بأمراض القلب اللازرقية الذين يخضعون للتصحيح الكامل بإستخدام الدلالة البولية الحديثة "كيم -1" Sarah Abdelsalam Elmetwally Kasem ; Supervised Azza Mohamed Ezzat , Wafaa Mohamed Alsadek , Olfat Gamil Shaker - Cairo : Sarah Abdelsalam Elmetwally Kasem , 2014 - 132 Leaves : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Anaesthesia
Cardiac surgery with cardiopulmonary bypass (CPB) is the most frequent major surgical procedure worldwide. Acute kidney injury (AKI) is a common and serious complication encountered in 3040% after CPB. Once AKI is established, there is no effective treatment for human AKI, and dialysis merely provides supportive care. There in lies the Achilles heel of AKI management ; the paucity of early biomarkers has lead to an unacceptable delay in initiating therapy in humans.Serum creatinine is insensitive for the early detection of AKI. KIM-1 is one of the most highly induced proteins in the kidney after AKI in animal models, and a proteolytically processed domain of KIM-1 is easily detected in the urine soon after AKI. In a small human cross-sectional study, KIM-1 expression was markedly induced in proximal tubules in kidney biopsies from patients with established AKI (primarily ischemic), and urinary KIM-1 measured by ELISA distinguished ischemic AKI from prerenal azotemia and chronic renal disease
AKI Cardiopulmonary bypass Dexmedetomidine